Most Read Articles
3 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
2 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 6 days ago
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).

Anti‐inflammatory therapy a win in checkpoint inhibitor‐induced enterocolitis

10 Oct 2020

Corticosteroids, infliximab, and vedolizumab are all beneficial in the treatment of patients with checkpoint inhibitor‐induced enterocolitis, according to a study.

Researchers conducted a systematic review and meta-analysis of studies evaluating the effectiveness of anti‐inflammatory therapy in checkpoint inhibitor‐induced enterocolitis. They searched multiple online databases and identified 39 studies eligible for inclusion.

The studies contributed to a total study population of 1,210 cancer patients who had developed immune checkpoint inhibitor‐induced enterocolitis and treated with anti‐inflammatory therapy. Cancer types included melanoma, lung cancer, urothelial cancer, prostate cancer, renal cell carcinoma, and Hodgkin's lymphoma, among others. Checkpoint inhibitors used were ipilimumab, tremelimumab, nivolumab, pembrolizumab, or anti‐PD‐L1. Corticosteroids and infliximab were the most frequently administered anti‐inflammatory agents.

Pooled data showed corticosteroids to be effective in 59 percent of the patients. The magnitude of effect varied by checkpoint inhibitor regimen and cancer type, such that corticosteroids produced a more favourable response among those treated with anti‐PD‐1/L1 monotherapy vs anti‐CTLA‐4 containing regimens (78 percent vs 56 percent; p=0.003) and among those with lung cancer vs melanoma (88 percent vs 55 percent; p=0.04).

Infliximab was effective in 81 percent of patients and vedolizumab, in 85 percent.

Associated with disabling symptoms and intestinal injury, checkpoint inhibitor‐induced enterocolitis is a common complication, which can lead to hospitalization and more serious conditions including intestinal perforation. The present data show that anti‐inflammatory agents have high success rates in the treatment of checkpoint inhibitor‐induced enterocolitis, the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
3 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
2 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 6 days ago
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).